Abstract
Treatment of actinic keratoses (AK) is a potentially effective strategy for prevention of cutaneous squamous cell carcinoma (cSCC). However, the patient perspective on potential benefits of AK treatment in terms of skin cancer reduction has received little attention to date.
Objectives
(1) To investigate patient preferences for AK topical treatments using a discrete choice experiment (DCE); (2) To evaluate patient willingness to trade between clinical benefit and medical burden.
Methods
The DCE was conducted as part of a study to establish the feasibility of a phase III RCT evaluating prevention of cSCC using currently available topical interventions. Preferences were elicited by asking patients to make a series of choices between treatment alternatives with different hypothetical combinations of attribute levels. Willingness to trade between treatment attributes was estimated using a flexible choice model that allows for the heterogeneity of patient preferences.
Results
109 patients with AK completed the DCE. The majority of patients who expressed valid preferences were willing to accept some reduction in both prophylactic and cosmetic efficacy to reduce the burden of the treatment regimen, the severity of skin reaction and other adverse effects. Patients may reject treatment if the perceived therapeutic benefit is outweighed by the subjective burden of treatment.
Conclusions
Evidence of significant variation in the perceived utility of treatments across patients highlights the importance of taking individual patient preferences into account to improve AK treatment acceptability and adherence.
| Original language | English |
|---|---|
| Pages (from-to) | 902-909 |
| Number of pages | 8 |
| Journal | British Journal of Dermatology |
| Volume | 180 |
| Issue number | 4 |
| Early online date | 26 Jul 2018 |
| DOIs | |
| Publication status | Published - Apr 2019 |
Fingerprint
Keywords
- CREAM
- PHOTODYNAMIC THERAPY
- SKIN-CANCER
- SQUAMOUS-CELL CARCINOMA
- TRANSPLANT RECIPIENTS
ASJC Scopus subject areas
- Dermatology
Cite this
Patient preferences for topical treatment of actinic keratoses : a discrete-choice experiment. / Kopasker, D.; Kwiatkowski, A.; Matin, R. N.; Harwood, C. A.; Ismail, F.; Lear, J. T.; Thomson, J.; Hasan, Z.; Wali, G. N.; Milligan, A.; Crawford, L.; Ahmed, I.; Duffy, H.; Proby, C. M.; Allanson, P. F. (Corresponding Author).
In: British Journal of Dermatology, Vol. 180, No. 4, 04.2019, p. 902-909.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Patient preferences for topical treatment of actinic keratoses
T2 - a discrete-choice experiment
AU - Kopasker, D.
AU - Kwiatkowski, A.
AU - Matin, R. N.
AU - Harwood, C. A.
AU - Ismail, F.
AU - Lear, J. T.
AU - Thomson, J.
AU - Hasan, Z.
AU - Wali, G. N.
AU - Milligan, A.
AU - Crawford, L.
AU - Ahmed, I.
AU - Duffy, H.
AU - Proby, C. M.
AU - Allanson, P. F.
N1 - Funding: This study was funded by the National Institute for Health Research (NIHR) Research for Patient Benefit programme (PB-PG-0110-21244), Department of Health, UK. The funder was not involved in the study design. Acknowledgments: The authors gratefully acknowledge support from the Cancer Research UK Clinical Trials Unit, the UK Dermatology Clinical Trials Network, the NIHR Clinical Studies Group, and support for investigators from the British Skin Foundation and Cancer Research UK. We would also like to thank Martin Jones, Daniel Rigby and Ariel Bergmann for constructive comments on the design of the DCE.
PY - 2019/4
Y1 - 2019/4
N2 - BackgroundTreatment of actinic keratoses (AK) is a potentially effective strategy for prevention of cutaneous squamous cell carcinoma (cSCC). However, the patient perspective on potential benefits of AK treatment in terms of skin cancer reduction has received little attention to date.Objectives(1) To investigate patient preferences for AK topical treatments using a discrete choice experiment (DCE); (2) To evaluate patient willingness to trade between clinical benefit and medical burden.MethodsThe DCE was conducted as part of a study to establish the feasibility of a phase III RCT evaluating prevention of cSCC using currently available topical interventions. Preferences were elicited by asking patients to make a series of choices between treatment alternatives with different hypothetical combinations of attribute levels. Willingness to trade between treatment attributes was estimated using a flexible choice model that allows for the heterogeneity of patient preferences.Results109 patients with AK completed the DCE. The majority of patients who expressed valid preferences were willing to accept some reduction in both prophylactic and cosmetic efficacy to reduce the burden of the treatment regimen, the severity of skin reaction and other adverse effects. Patients may reject treatment if the perceived therapeutic benefit is outweighed by the subjective burden of treatment.ConclusionsEvidence of significant variation in the perceived utility of treatments across patients highlights the importance of taking individual patient preferences into account to improve AK treatment acceptability and adherence.
AB - BackgroundTreatment of actinic keratoses (AK) is a potentially effective strategy for prevention of cutaneous squamous cell carcinoma (cSCC). However, the patient perspective on potential benefits of AK treatment in terms of skin cancer reduction has received little attention to date.Objectives(1) To investigate patient preferences for AK topical treatments using a discrete choice experiment (DCE); (2) To evaluate patient willingness to trade between clinical benefit and medical burden.MethodsThe DCE was conducted as part of a study to establish the feasibility of a phase III RCT evaluating prevention of cSCC using currently available topical interventions. Preferences were elicited by asking patients to make a series of choices between treatment alternatives with different hypothetical combinations of attribute levels. Willingness to trade between treatment attributes was estimated using a flexible choice model that allows for the heterogeneity of patient preferences.Results109 patients with AK completed the DCE. The majority of patients who expressed valid preferences were willing to accept some reduction in both prophylactic and cosmetic efficacy to reduce the burden of the treatment regimen, the severity of skin reaction and other adverse effects. Patients may reject treatment if the perceived therapeutic benefit is outweighed by the subjective burden of treatment.ConclusionsEvidence of significant variation in the perceived utility of treatments across patients highlights the importance of taking individual patient preferences into account to improve AK treatment acceptability and adherence.
KW - CREAM
KW - PHOTODYNAMIC THERAPY
KW - SKIN-CANCER
KW - SQUAMOUS-CELL CARCINOMA
KW - TRANSPLANT RECIPIENTS
UR - http://www.scopus.com/inward/record.url?scp=85051117452&partnerID=8YFLogxK
UR - http://www.mendeley.com/research/patient-preferences-topical-treatment-actinic-keratoses-discretechoice-experiment-1
UR - https://abdn.pure.elsevier.com/en/en/researchoutput/patient-preferences-for-topical-treatment-of-actinic-keratoses(0259c3d8-c591-4f50-a180-255c33b06a50).html
U2 - 10.1111/bjd.16801
DO - 10.1111/bjd.16801
M3 - Article
VL - 180
SP - 902
EP - 909
JO - British Journal of Dermatology
JF - British Journal of Dermatology
SN - 0007-0963
IS - 4
ER -